Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Transactions

Chief Financial Officer Ian Michael Estepan of Sarepta Therapeutics reports transactions involving common stock, performance stock units, and stock options.

Summary

• Ian Michael Estepan, CFO of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 7, 2025, 5,500 performance stock units (PSUs) vested, resulting in the acquisition of 5,500 shares of common stock.
• On March 10, 2025, 1,051 shares were sold to cover tax obligations related to vesting restricted stock units at a price of $100.13.
• An additional 2,890 shares were sold on March 10, 2025, at $100.13 to cover tax obligations related to the vesting of PSUs.
• Estepan was granted 8,276 restricted stock units (RSUs) on March 10, 2025, each representing the right to receive one share of common stock, vesting in equal installments over four years.
• Estepan was also granted stock options to purchase 16,644 shares of common stock at an exercise price of $99.69, vesting monthly over four years starting March 10, 2026.
• Following these transactions, Estepan directly owns 62,612 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The granting of RSUs and stock options to the CFO suggests a continued investment in the company's future.

Future Outlook

The reported transactions reflect ongoing compensation and equity incentives for the CFO, with vesting schedules extending into the future.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Equity compensation practices, including the use of stock options and restricted stock units, are common among publicly traded biotechnology companies like Sarepta Therapeutics to attract and retain key executives.
• Companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies.
• The vesting schedules and exercise prices are generally in line with industry norms for executive compensation packages.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they relate to executive compensation and do not indicate a change in the company's overall financial health.

Key Dates